Sutureless aortic valve replacement in high risk patients neutralizes expected worse hospital outcome: A clinical and economic analysis
Abstract
Background: Aortic valve replacement (AVR) by sutureless prostheses is changing surgeon options, although which patients benefit most, as well as their possible economic impact is still to be defined.
Methods: Perceval-S prosthesis (LivaNova) is reserved, at the documented Institution, for patients at perceived high surgical risk. This retrospective analysis of outcome and resource consumption compared Perceval with other tissue valves. To clarify the comparison, only patients respecting ‘instructions-for- use’ of Perceval were reviewed. Inclusion criteria: > 65 years, +/– coronary artery bypass grafting, patent foramen ovale closure or myectomy. Exclusion criteria: bicuspid, combined valve or aortic sur- gery. Costs were calculated per patient on a daily basis including preoperative tests, operating costs (hourly basis), disposables, drugs, blood components and personnel.
Results: The sutureless group (SU-AVR) had a higher risk profile than the sutured group (ST-AVR). Cardiopulmonary bypass (CPB) and cross-clamp times were significantly shorter in SU-AVR (isolated AVR: cross-clamp 52.9 ± 12.6 vs. 69 ± 15.3 min, p < 0.001; CPB 79.4 ± 20.3 vs. 92.7 ± 18.2 min, p < 0.001). Hospital mortality was 0.9% in SU-AVR and nil in ST-AVR, p = 0.489; intubation 7 (IQR 5–10.7) and 7 h (IQR 5–9), p = 0.785; intensive care unit 1 (IQR 1–1) and 1 day (IQR 1–1), p = 0.258; ward stay 5.5 (IQR 4–7) and 5 days (IQR 4–6), p = 0.002; pacemaker 5.7% (6/106) and 0.9% (1/109), p = 0.063, respectively. Hospital costs (excluding the prosthesis) were $12,825 (IQR 11,733–15,334) for SU-AVR and $12,386 (IQR 11,217–14,230) in ST-AVR, p = 0.055.
Conclusions: Despite higher operative risks in SU-AVR, hospital mortality, morbidity and resource consumption did not differ. Operative times were shorter with the sutureless device and this improve- ment, along with more frequent ministernotomy, may have improved many postoperative aims.
Keywords: suturelesspercevalaortic valve
References
- Max Roser (2016) – ‘Life Expectancy’. Published online at OurWorldInData.org. https://ourworldindata.org/life-expectancy/ (Online Resource).
- Badheka AO, Singh V, Patel NJ, et al. Trends of Hospitalizations in the United States from 2000 to 2012 of Patients >60 Years With Aortic Valve Disease. Am J Cardiol. 2015; 116(1): 132–141.
- Canadian Agency for Drugs and Technologies in Health: Perceval S Sutureless Valve for Aortic Valve Replacement: A Review of the Clinical Effectiveness, Safety, and Cost-Effectiveness [Internet]. Ottawa (ON); 2015 Jan 29. http://www.ncbi.nlm.nih.gov/books/NBK349716/.
- Di Eu, Phan K. Sutureless aortic valve replacement. Ann Cardiothorac Surg. 2015; 4(2): 123–130.
- Al-Sarraf N, Thalib L, Hughes A, et al. Cross-clamp time is an independent predictor of mortality and morbidity in low- and high-risk cardiac patients. Int J Surg. 2011; 9(1): 104–109.
- Pradelli L, Zaniolo O. Perceval Sutureless valves in isolated and concomitant AVR procedures: an economic model shows overall decrease of costs for isolated or combined operations. Farmeconomia. Health Economics and Therapeutic Pathways. 2012; 13(4): 159.
- http://www.inflation.eu/inflation-rates/italy/inflation-italy.aspx.
- Pollari F, Santarpino G, Dell'Aquila AM, et al. Better short-term outcome by using sutureless valves: a propensity-matched score analysis. Ann Thorac Surg. 2014; 98(2): 611–616; discussion 616.
- Paparella D, Rotunno C, Guida P, et al. Minimally invasive heart valve surgery: influence on coagulation and inflammatory response. Interact Cardiovasc Thorac Surg. 2017; 25(2): 225–232.
- Albayati MA, Grover SP, Saha P, et al. Postsurgical Inflammation as a Causative Mechanism of Venous Thromboembolism. Semin Thromb Hemost. 2015; 41(6): 615–620.
- Villa E, Messina A, Tomba M, et al. Ministernotomy reduces intubation time in aortic valve replacement with Perceval prosthesis. J Cardiothoracic Surgery. 2015; 10(S1).
- Karangelis D, Mazine A, Roubelakis A, et al. What is the role of sutureless aortic valves in today's armamentarium? Expert Rev Cardiovasc Ther. 2017; 15(2): 83–91.
- Sánchez E, Corrales JA, Fantidis P, et al. Thrombocytopenia after Aortic Valve Replacement with Perceval S Sutureless Bioprosthesis. J Heart Valve Dis. 2016; 25(1): 75–81.
- Santarpino G, Fischlein T, Pfeiffer S. A word of caution is needed before uttering a word of caution: thrombocytopenia and sutureless valves. Heart Surg Forum. 2016; 19(4): E169.
- Minami T, Sainte S, De Praetere H, et al. Hospital cost savings and other advantages of sutureless vs stented aortic valves for intermediate-risk elderly patients. Surg Today. 2017; 47(10): 1268–1273.
- Stanger O, Grabherr M, Gahl B, et al. Thrombocytopaenia after aortic valve replacement with stented, stentless and sutureless bioprostheses. Eur J Cardiothorac Surg. 2017; 51(2): 340–346.
- Laborde F, Folliguet T, Ghorayeb G, et al. Sutureless valves reduce hospital costs compared to traditional valves. J Heart Valve Dis. 2017; 26(1): 1–8.
- McCarthy FH, Savino DC, Brown CR, et al. Cost and contribution margin of transcatheter versus surgical aortic valve replacement. J Thorac Cardiovasc Surg. 2017; 154(6): 1872–1880.e1.
- Ailawadi G, LaPar DJ, Speir AM, et al. Contemporary costs associated with transcatheter aortic valve replacement: a propensity-matched cost analysis. Ann Thorac Surg. 2016; 101(1): 154–60; discussion 160.
- Ghanta RK, Lapar DJ, Kern JA, et al. Minimally invasive aortic valve replacement provides equivalent outcomes at reduced cost compared with conventional aortic valve replacement: A real-world multi-institutional analysis. J Thorac Cardiovasc Surg. 2015; 149(4): 1060–1065.
- Aldalati O, MacCarthy P, Dworakowski R. Trans-catheter aortic valve implantation: Contemporary practice and the future. Cardiol J. 2017; 24(2): 206–215.
